TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05991076

Intervention type: OTHER
Intervention: Latin Dance
Description: The Activate Bailando class is a dance-focused exercise class that is offered once per week for one hour. The program has been developed by dance educators in the Madison area.
Study: NCT06362811

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral Erector Spinae Plane Block
Description: Ultrasound-guided bilateral injection of 1ml/kg 0.25% bupivacaine into the plane underneath the erector spinae muscles over sacral crests. The needle is inserted with in-plane technique from cranial to caudal direction over S3-4.
Study: NCT05773287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Health Coaching Group
Description: Participants in the THC group will receive an exercise prescription (steps/day) based on their last cardiac rehabilitation session exercise prescription. Participants will be provided a Garmin wearable device to track steps/day. Additionally, participants will partake in 6 virtual or in-person health coaching sessions lasting approximately 30-60 minutes in duration. These sessions will take place approximately every other week during the 3-month intervention period.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care Group
Description: Participants in the SC group will receive an exercise prescription (steps/day) based on their last cardiac rehabilitation session exercise prescription. Participants will be provided a Garmin wearable device to track steps/day. Additionally, participants will be provided with a single virtual or in-person education session, lasting approximately 30 minutes, at the beginning of the 3-month intervention period.
Study: NCT06437860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIND Diet
Description: Daily meals designed to increase adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) dietary pattern.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Diet
Description: Daily meals designed to increase fruit, vegetable, and whole grain intake consistent with a healthy American diet.
Study: NCT05693441

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active berry product
Description: Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reference berry-like product
Description: Subjects should consume a reference product (isocaloric to active product, containing berry aromas and colouring but no actual berry compounds) daily during the 12 week intervention period.
Study: NCT06501482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postoperative reintroduction of FOLFIRI based chemotherapy
Description: Postoperative reintroduction of FOLFIRI: irinotecan 180 mg/m2 + leucovorin 400 mg/m2 at day 1 then 5-FU 400 mg/m2 bolus followed by 2400 mg/m2 continuous infusion over 46 h biweekly. For a total of 12 cycles of perioperative chemotherapy including the preoperative chemotherapy
Study: NCT03810898

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioligand [¹¹C]CHDI-00485180-R
Description: Intravenous injection of radioligand in the arm with PET imaging of the brain.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioligand [¹¹C]CHDI-00485180-R
Description: Intravenous injection of radioligand in the arm with PET imaging of the brain.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioligand [¹¹C]CHDI-00485180-R
Description: Intravenous injection of radioligand in the arm with PET imaging of the brain.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioligand [¹¹C]CHDI-00485180-R
Description: Intravenous injection of radioligand in the arm with PET imaging of the brain.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioligand [¹¹C]CHDI-00485626
Description: Intravenous injection of radioligand in the arm with PET imaging of the brain.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioligand [¹¹C]CHDI-00485626
Description: Intravenous injection of radioligand in the arm with PET imaging of the brain.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioligand [¹¹C]CHDI-00485626
Description: Intravenous injection of radioligand in the arm with PET imaging of the brain.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioligand [¹¹C]CHDI-00485626
Description: Intravenous injection of radioligand in the arm with PET imaging of the brain.
Study: NCT06286904

Intervention type: DEVICE
Intervention: Skiin Garment system
Description: Individuals will be asked to wear a Skiin Garment system for the duration of their hospitalization (minimum one day).The system will collect accelerometer, ECG, temperature, heart rate, steps and sleep metrics data if enable. Then, they will be asked to answer a questionnaire about their experiences with the device and the study.
Study: NCT04219319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of LCAR-T2C CAR-T cells
Description: CD4-directed CAR-T cells administered with lymphodepletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
Study: NCT06234007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine
Description: Safety run-in phase: Fruquintinib 4mg/d, oral, once daily, continuous treatment for 2 weeks, 1 week off, q3w, 6 cycles; If the number of patients experiencing dose-limiting toxicity (DLT) was ≤1, the study would continue at that dose level. If the number of patients with DLTs was \>1, the dose of fruquintinib was decreased to 3mg/d, qd po, d1-14, q3w, and the dose expansion phase was continued；Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;~Dose expansion phase: Fruquintinib RP2D, qd po, d1-14, q3w, 6 cycles; Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;
Study: NCT03935724

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neuro-Cells
Description: Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Neuro-Cells
Description: Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
Study: NCT04406818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Dioxide
Description: Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Dioxide
Description: Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity
Study: NCT04873232

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engensis
Description: Injections with Engensis in study VMDN-003-2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injections with Placebo in study VMDN-003-2
Study: NCT04657211

Intervention type: OTHER
Intervention: prospective observational cohort study
Description: prospective observational cohort study

Intervention type: OTHER
Intervention: prospective observational cohort study
Description: prospective observational cohort study

Intervention type: OTHER
Intervention: prospective observational cohort study
Description: prospective observational cohort study
Study: NCT05367440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5305
Description: Patients will receive an oral dose of AZD5305 once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5305
Description: Patients will receive an oral dose of AZD5305 once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5305
Description: Patients will receive an oral dose of AZD5305 once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Patients will receive an oral dose of Enzalutamide once daily
Study: NCT05571098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individualized colorectal cancer education
Description: Subjects taught within the scope of individualized colorectal cancer education:~* Common symptoms and management related to disease and treatment,~* Importance of nutrition in the treatment process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psycho-oncological counseling
Description: Topics discussed within the scope of psycho-oncological counseling:~* Psychological state (anxiety, depression, etc.),~* Coping strategies about the process,~* Presence of fear about the disease and/or treatment,~* Lifestyle changes/problems,~* Changes in body image,~* Family/friendship/work-related concerns,~* Additional issues, comments he wishes to convey

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone support hotline service
Description: Within the scope of the NNP, a telephone support hotline service was provided to the participants, where they could consult at any time about the subject they wanted.
Study: NCT06118541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation therapy
Description: Vestibular rehabilitation exercises of 30 to 60 minutes twice a week for eight weeks~Vestibular rehabilitation exercise program:~1. Eye-Head Coordination exercise~2. Sitting balance exercises~3. Standing Static balance exercises~4. Standing Dynamic balance exercises~5. Ambulation exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation therapy
Description: Vestibular rehabilitation exercises of 30 to 60 minutes twice a week for eight weeks~Vestibular rehabilitation exercise program:~1. Eye-Head Coordination exercise~2. Sitting balance exercises~3. Standing Static balance exercises~4. Standing Dynamic balance exercises~5. Ambulation exercises
Study: NCT05718752

Intervention type: DIAGNOSTIC_TEST
Intervention: Maximal incremental exercise test
Description: Gas exchange are measured during all the test on ergocycle until oxygen consumption reach its maximum value

Intervention type: DIAGNOSTIC_TEST
Intervention: Maximal incremental exercise test
Description: Gas exchange are measured during all the test on ergocycle until oxygen consumption reach its maximum value

Intervention type: DIAGNOSTIC_TEST
Intervention: 30-min submaximal exercise test
Description: A 30-min submaximal test on ergocycle. Gas exchange are measured during all the test. Blood samples are collected before, at the end of exercise and after 3 hours of recovery

Intervention type: DIAGNOSTIC_TEST
Intervention: 30-min submaximal exercise test
Description: A 30-min submaximal test on ergocycle. Gas exchange are measured during all the test. Blood samples are collected before, at the end of exercise and after 3 hours of recovery
Study: NCT05353712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUCROSE
Description: 50g sweet creme composed of 14.3g vegetable fat and 35.7g sucrose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUCROSE
Description: 50g sweet creme composed of 14.3g vegetable fat and 35.7g sucrose.
Study: NCT06455371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision support tool
Description: Patients in the intervention groups are given the option to use the decision support tool when adjusting the levothyroxine dose after total thyroidectomy. Levothyroxine therapy is not a part of the intervention, as all patients receive this therapy regardless of study participation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision support tool
Description: Patients in the intervention groups are given the option to use the decision support tool when adjusting the levothyroxine dose after total thyroidectomy. Levothyroxine therapy is not a part of the intervention, as all patients receive this therapy regardless of study participation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision support tool
Description: Patients in the intervention groups are given the option to use the decision support tool when adjusting the levothyroxine dose after total thyroidectomy. Levothyroxine therapy is not a part of the intervention, as all patients receive this therapy regardless of study participation.
Study: NCT06335914

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ga 68 PSMA-11 PET
Description: Positron emission tomography (PET) imaging using Ga68 PSMA 11 radiotracer

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL PET
Description: Positron emission tomography (PET) imaging using 18F-DCFPyL radiotracer.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG PET
Description: Positron emission tomography (PET) imaging using (18) F-fluorodeoxyglucose radiotracer.
Study: NCT06494839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipolar electrocautery tonsillectomy technique
Description: The BED tonsillectomy procedures were done under general anesthesia, and the patient's position was the same as in the other method. The bipolar machine was adjusted to 30 watts, and a mucosal incision was cauterized with a single straight or stepped bipolar forceps. After carefully cauterizing the tissue, the palatine tonsil was located and removed from the superior to the inferior pole. Most of the identifiable vessels supplying the tonsil were cauterized before being separated from the tonsil. Point coagulation was used to maintain hemostasis. By using point coagulation, hemostasis was maintained. To avoid bias stemming from competence, consultants performed all of these tonsillectomies.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold steel dissection technique
Description: The cold steel blunt dissection tonsillectomy was carried out under general anesthesia while the patient was in the Rose position and had an endotracheal intubation. The tonsil was retracted medially with a tonsil holding forceps, and in the upper pole, the mucosal incision was made. To protect the tonsillar pillars, a delicate dissection was performed, and the suction tip was used to stop the hemorrhage. The tonsillar fossa was packed with swabs. The other palatine tonsil was then similarly removed. Hemostasis was secured by silk ligation and bipolar electrocautery.
Study: NCT04208984

Intervention type: DEVICE
Intervention: Study
Description: After consent and assent the child and parent will be introduced the Lullabreath in pre-op. The purpose of Lullabreath will be explained and the Lullabreath will be taught (15 minutes). The parent will complete the PROMIS Proxy Anxiety short form. The children are then taken to the operating room (leave parents) with the Lullabreath. The anesthesiologist will hook the device up to the anesthesia circuit and start the Lullabreath. The child will then undergo induction of anesthesia while playing the Lullabreath.

Intervention type: OTHER
Intervention: Music Video
Description: After consent and assent the child and parent will be introduced to the game in pre-op. The purpose of the game will be explained and the game will be taught (15 minutes). The parent will complete the PROMIS Proxy Anxiety short form. The children are then taken to the operating room (leave parents) with the game. The anesthesiologist will hook the device up to the anesthesia circuit and start the game. The child will then undergo induction of anesthesia while playing the game. The child can choose to watch one of two music videos (Frozen, Lion King)
Study: NCT05255406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib (160mg)
Description: 160mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (80mg).
Study: NCT05367440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Patients will receive an oral dose of Abiraterone Acetate once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Patients will receive an oral dose of Darolutamide twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Patients will receive an oral dose of Apalutamide once daily
Study: NCT05647265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04894903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Care Gaps Patient Portal Intervention
Description: The Diabetes Care Gaps Patient Portal Intervention is embedded within an existing patient web portal (My Health at Vanderbilt). The intervention (a) notifies patients when selected, clinically meaningful, evidence-based diabetes monitoring \& preventative care (e.g., annual urine microalbumin) are due and (b) allows patients to initiate orders for the care.
Study: NCT03649464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN-007
Description: Dose escalation/PK cohort (Phase Ib): 1000mg twice daily (BID), 1000mg thrice daily (TID), 1500mg thrice daily (TID).~Expansion cohort (Phase 2): MTD defined in the dose escalation (Phase Ib) study.
Study: NCT05850572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation(FMT)
Description: Subjects will receive FMT capsules (10\^12 CFU/capsule) in addition to their usual antidepressant treatment. Subjects will continue to receive FMT capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antidepressant treatment. Placebo capsules contained the food probiotic Lactobacillus (10\^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
Study: NCT06509646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tia Chi Exercise
Description: • Yang style 24-posture short-form (16) for 30 minute It consists of 24 unique movements that are performed in a sequence. The form is designed to be easy to learn and can be completed in about six minutes.~Treatment dosage will be 1 session per day of 1 hour class, 2 sets per session, and 5 repetitions per set, 3 times per week and for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frenkel's Exercise
Description: Frenkel's exercises 30 minutes (Through these exercises, the patients would learn how to stay balanced and prevent falls by using their visual, somatosensory, and vestibular systems).~Treatment dosage will be 1 session per day of 1 hour class, 2 sets per session, and 5 repetitions per set, 3 times per week and for 12 weeks
Study: NCT05993260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural science-informed text messages
Description: Behaviourally-informed content in vaccination eligibility reminder text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural science-informed text messages
Description: Behaviourally-informed content in vaccination eligibility reminder text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural science-informed text messages
Description: Behaviourally-informed content in vaccination eligibility reminder text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural science-informed text messages
Description: Behaviourally-informed content in vaccination eligibility reminder text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural science-informed text messages
Description: Behaviourally-informed content in vaccination eligibility reminder text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural science-informed text messages
Description: Behaviourally-informed content in vaccination eligibility reminder text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural science-informed text messages
Description: Behaviourally-informed content in vaccination eligibility reminder text messages

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control vaccination eligibility reminder text message
Study: NCT04827927

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure: INTELLiVENT-ASV
Description: With INTELLiVENT-ASV, the patient's conditions, 'ARDS', 'Chronic Hypercapnia' or 'Traumatic Brain Injury' can be chosen, if applicable. The controllers for minute volume, PEEP and FiO2 are all activated, and the target shifts for etCO2 and SpO2 are adjusted, if necessary.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: Conventional ventilation
Description: With conventional ventilation, the same etCO2 and SpO2 levels are targeted as with INTELLiVENT-ASV, but here the caregiver is fully responsible for choosing the settings.
Study: NCT05403125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silver diamine fluoride, 38%
Description: Topical application to all surfaces of the teeth

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride gel, 5000 PPM
Description: Gel applied after application of silver diamine fluoride and dispensed for home use

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sodium fluoride gel, 5000 PPM
Description: Gel applied after application of silver diamine fluoride and dispensed for home use